Pharmaceutical industry
The Australian sharemarket closed 1996 on a high note, driven by interest rate cuts and a recovering All Ordinaries index. Despite concerns about the potential impact of a correction on Wall Street, analysts believe Australian shares offer better value than their US counterparts. Adelaide brokers have identified several local and
Pharmaceutical industry
Genetics Institute, a leading biopharmaceutical firm, is set to become a wholly-owned subsidiary of American Home Products Corporation after exercising a call option to acquire the outstanding capital stock. This move comes on the heels of American Home Products Corporation's notice of intent to exercise the call option
Pharmaceutical industry
Multiple companies have secured significant government contracts and completed high-profile mergers in recent deals. BDM International Inc.'s BDM Federal unit won a contract worth $11.7 million to provide interpreters for American military personnel in Bosnia and Hungary, while CACI International Inc. secured a $66 million subcontract to
Pharmaceutical industry
Rhone-Poulenc Rorer Inc. (RPR) and Enzon, Inc. have announced a licensing agreement for Enzon's Single-Chain Antigen-Binding (SCA) protein technology, which will be used for intracellular expression of SCA proteins and targeted vectors in the field of cell and gene therapy. This technology will be applied to RPR'
Pharmaceutical industry
A significant advancement in the treatment of vaginal yeast infections has been achieved with the approval of FEMSTAT 3, an over-the-counter (OTC) treatment developed by the Procter & Gamble Company and Roche Holding Ltd. This product will be the first and only 3-day treatment brand available without a prescription, marking
Drugs
Micros-to-Mainframes, Inc. (MTM), a leading provider of advanced technology and communications products, has signed a significant national hardware and software supply contract with Ciba-Geigy Corporation, a prominent pharmaceutical company. The three-year agreement names MTM as the preferred vendor for computer hardware and supplies at 47 Ciba-Geigy locations across North America
Drugs
Schering-Plough Corporation, a leading biotechnology company, has announced an agreement to acquire Canji, a privately held gene therapy company, for $54.5 million in Schering-Plough stock and rights to participate in royalties on certain products. This acquisition represents a significant step for Schering-Plough in its commitment to gene therapy research,
Drugs
John E. Nine, the president of technical operations at Schering Laboratories, has been elected by the Board of Directors as a corporate vice president of Schering-Plough Corporation, effective January 1, 1996. In his new position, Nine will oversee all major capital construction projects worldwide and serve as head of the
Pharmaceutical industry
Consumers Power Company, a subsidiary of CMS Energy Corporation, has signed a 10-year agreement with Pharmacia & Upjohn to provide discounted electricity to the pharmaceutical company's Kalamazoo and Portage facilities. The deal will see Consumers Power supply approximately 75 megawatts of electricity to Pharmacia & Upjohn's
Pharmaceutical industry
Sales Technologies, Inc. (ST) has announced a partnership with Roche Laboratories following a competitive selection process. Roche will use ST's product, SNAP/Pharma, to support the team selling, managed care, and micro-marketing initiatives across the entire sales and marketing organization. This partnership is significant as it demonstrates the
Pharmaceutical industry
Regeneron Pharmaceuticals, led by President and CEO Dr. Leonard S. Schleifer, made several notable announcements at the Robertson Stephens & Company 1995 Medical Conference in New York City. The company highlighted significant progress in its research and development programs, including the BDNF clinical trial for amyotrophic lateral sclerosis (ALS) and
Pharmaceutical industry
ImaRx Pharmaceutical Corp., a privately held biotechnology company based in Tucson, Ariz., has announced a licensing agreement with DuPont Merck for MRX-115 Aerosomes(R), a second-generation ultrasound contrast agent with applications for cardiac and blood pool imaging. The agreement marks a significant step forward for ImaRx, as DuPont Merck will
